Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.

ABSTRACT: Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.

SUBMITTER: Titanji BK 

PROVIDER: S-EPMC7337637 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature